Akari Therapeutics, Plc Retained Earnings
Akari Therapeutics, Plc (AKTX) had Retained Earnings of -$283.81 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:RetainedEarningsAccumulatedDeficit · last filed 2026-08-13
- 2026-06-30: Retained Earnings (Accumulated Deficit) -$283.81M.
- 2026-03-31: Retained Earnings (Accumulated Deficit) -$279.00M.
- 2025-12-31: Retained Earnings (Accumulated Deficit) -$264.55M.
- 2025-09-30: Retained Earnings (Accumulated Deficit) -$259.25M.
| Period end | Retained Earnings (Accumulated Deficit) | Retained Earnings (Accumulated Deficit) as first filed |
|---|---|---|
| 2026-06-30 | -$283.81M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$279.00M 10-Q · filed 2026-05-19 | |
| 2025-12-31 | -$264.55M 10-Q · filed 2026-08-13 | |
| 2025-09-30 | -$259.25M 10-Q · filed 2025-11-13 | |
| 2025-06-30 | -$252.85M 10-Q · filed 2025-08-13 | |
| 2025-03-31 | -$250.96M 10-Q · filed 2025-05-14 | |
| 2024-12-31 | -$247.25M 10-K · filed 2026-03-30 | |
| 2024-09-30 | -$243.48M 10-Q · filed 2024-11-19 | |
| 2024-06-30 | -$42.68M 8-K · filed 2024-09-06 | -$240.59M 10-Q · filed 2024-08-19 |
| 2024-03-31 | -$233.03M 10-Q · filed 2024-05-15 | |
| 2023-12-31 | -$227.46M 10-K · filed 2025-04-15 | |
| 2023-06-30 | -$220.45M 6-K · filed 2023-09-29 | |
| 2022-12-31 | -$25.35M 8-K · filed 2024-09-06 | -$217.45M 20-F · filed 2023-05-01 |
| 2022-06-30 | -$210.56M 6-K · filed 2022-09-27 | |
| 2021-12-31 | -$199.71M 20-F · filed 2023-05-01 | |
| 2021-06-30 | -$192.47M 6-K · filed 2021-09-22 | |
| 2020-12-31 | -$182.28M 20-F · filed 2022-05-16 | |
| 2020-09-30 | -$175.47M 20-F · filed 2021-04-21 | |
| 2020-06-30 | -$176.38M 20-F · filed 2021-04-21 | -$155.61M 6-K · filed 2020-09-01 |
| 2020-03-31 | -$168.94M 20-F · filed 2021-04-21 | |
| 2019-12-31 | -$165.20M 20-F · filed 2021-04-21 | -$143.91M 20-F · filed 2020-03-31 |
| 2019-09-30 | -$157.37M 20-F · filed 2021-04-21 | |
| 2019-06-30 | -$154.49M 20-F · filed 2021-04-21 | -$133.47M 6-K · filed 2019-08-29 |
| 2019-03-31 | -$148.54M 20-F · filed 2021-04-21 | |
| 2018-12-31 | -$126.80M 20-F · filed 2020-03-31 | |
| 2018-06-30 | -$119.70M 6-K · filed 2018-09-27 | |
| 2017-12-31 | -$110.34M 20-F · filed 2019-04-23 | |
| 2017-06-30 | -$87.84M 6-K · filed 2017-08-10 | |
| 2016-12-31 | -$74.94M 20-F · filed 2018-07-18 | |
| 2016-06-30 | -$66.23M 6-K · filed 2017-04-14 | |
| 2016-03-31 | -$59.78M 10-Q · filed 2016-05-12 | |
| 2015-12-31 | -$56.80M 6-K · filed 2017-04-14 | |
| 2015-09-30 | -$63.27M 10-Q · filed 2015-11-23 | |
| 2015-06-30 | -$34.18M 10-Q · filed 2015-08-12 | |
| 2015-03-31 | -$32.51M 10-Q · filed 2015-05-12 | |
| 2014-12-31 | -$11.48M 10-K · filed 2016-03-23 | -$30.19M 10-K · filed 2015-02-11 |
| 2013-12-31 | -$20.54M 10-K · filed 2015-02-11 | |
| 2012-12-31 | -$16.92M 20-F · filed 2014-03-24 | |
| 2011-12-31 | -$12.62M 20-F/A · filed 2013-04-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ELI LILLY & Co (LLY) | United States | $1,113.804B | 42.28 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| AbbVie Inc. (ABBV) | United States | $468.180B | 70.37 |
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |